Publications by authors named "Kathleen Swoap"
Brain Behav Immun
May 2017
Article Synopsis
- Glioblastoma (GBM) is a highly aggressive brain tumor with a median survival of about 14.6 months, largely due to the presence of the immunosuppressive enzyme IDO1, which converts tryptophan into kynurenine (Kyn).
- Research using a mouse model has shown that while tumor cell IDO1 contributes to immunosuppression, it is actually non-tumor cells that play a major role in IDO1 activity and influence tumor immunity.
- The findings indicate that the benefits of immune checkpoint blockade in GBM treatment depend on non-tumor cell IDO1 activity, suggesting that selecting the right IDO1 inhibitors could enhance the effectiveness of immunotherapies in patients
